Novartis: Novartis, FDA Battle Over Generic Drug Labeling in DC Circuit

A three-judge panel wrestled Thursday with Novartis AG's challenge against the FDA over its approval of a generic version of its heart failure drug, pressing both the manufacturer and agency on the accuracy of the drug labels.